792 related articles for article (PubMed ID: 21036792)
21. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
Rapti I; Dimou E; Mitsoula P; Hadziyannis SJ
Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
[TBL] [Abstract][Full Text] [Related]
22. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
[TBL] [Abstract][Full Text] [Related]
23. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus.
Snow-Lampart A; Chappell B; Curtis M; Zhu Y; Myrick F; Schawalder J; Kitrinos K; Svarovskaia ES; Miller MD; Sorbel J; Heathcote J; Marcellin P; Borroto-Esoda K
Hepatology; 2011 Mar; 53(3):763-73. PubMed ID: 21374657
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B virus wild-type and rtN236T populations show similar early HBV DNA decline in adefovir refractory patients on a tenofovir-based regimen.
Svarovskaia ES; Curtis M; Zhu Y; Borroto-Esoda K; Miller MD; Berg T; Lavocat F; Zoulim F; Kitrinos KM
J Viral Hepat; 2013 Feb; 20(2):131-40. PubMed ID: 23301548
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues.
van Bömmel F; de Man RA; Wedemeyer H; Deterding K; Petersen J; Buggisch P; Erhardt A; Hüppe D; Stein K; Trojan J; Sarrazin C; Böcher WO; Spengler U; Wasmuth HE; Reinders JG; Möller B; Rhode P; Feucht HH; Wiedenmann B; Berg T
Hepatology; 2010 Jan; 51(1):73-80. PubMed ID: 19998272
[TBL] [Abstract][Full Text] [Related]
26. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Heathcote EJ; Marcellin P; Buti M; Gane E; De Man RA; Krastev Z; Germanidis G; Lee SS; Flisiak R; Kaita K; Manns M; Kotzev I; Tchernev K; Buggisch P; Weilert F; Kurdas OO; Shiffman ML; Trinh H; Gurel S; Snow-Lampart A; Borroto-Esoda K; Mondou E; Anderson J; Sorbel J; Rousseau F
Gastroenterology; 2011 Jan; 140(1):132-43. PubMed ID: 20955704
[TBL] [Abstract][Full Text] [Related]
27. Suboptimal response to adefovir dipivoxil therapy for chronic hepatitis B in nucleoside-naive patients is not due to pre-existing drug-resistant mutants.
Carrouée-Durantel S; Durantel D; Werle-Lapostolle B; Pichoud C; Naesens L; Neyts J; Trépo C; Zoulim F
Antivir Ther; 2008; 13(3):381-8. PubMed ID: 18572751
[TBL] [Abstract][Full Text] [Related]
28. Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy.
Wang LC; Chen EQ; Cao J; Liu L; Wang JR; Lei BJ; Tang H
J Viral Hepat; 2010 Mar; 17(3):178-84. PubMed ID: 19656287
[TBL] [Abstract][Full Text] [Related]
29. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
Yang HJ; Lee JH; Kim YJ; Yoon JH; Lee HS
J Med Virol; 2012 Mar; 84(3):424-30. PubMed ID: 22246827
[TBL] [Abstract][Full Text] [Related]
30. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations.
Tan J; Degertekin B; Wong SN; Husain M; Oberhelman K; Lok AS
J Hepatol; 2008 Mar; 48(3):391-8. PubMed ID: 18199519
[TBL] [Abstract][Full Text] [Related]
31. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
[TBL] [Abstract][Full Text] [Related]
32. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
[TBL] [Abstract][Full Text] [Related]
33. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
Yue W; Yuan H; Mao XR; Deng YD; Chen L
Zhonghua Gan Zang Bing Za Zhi; 2013 Mar; 21(3):184-8. PubMed ID: 23967738
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B.
Gallego A; Sheldon J; García-Samaniego J; Margall N; Romero M; Hornillos P; Soriano V; Enrĺquez J
J Viral Hepat; 2008 May; 15(5):392-8. PubMed ID: 18221300
[TBL] [Abstract][Full Text] [Related]
35. Simple scoring system predicting genotypic resistance during rescue therapy for Lamivudine-resistant chronic hepatitis B.
Lee JH; Yoon JH; Cho EJ; Yang HJ; Jang ES; Kwak MS; Hwang SY; Yu SJ; Lee CH; Kim YJ; Kim CY; Lee HS
J Clin Gastroenterol; 2012 Mar; 46(3):243-50. PubMed ID: 21716122
[TBL] [Abstract][Full Text] [Related]
36. Entecavir plus tenofovir versus entecavir plus adefovir in chronic hepatitis B patients with a suboptimal response to lamivudine and adefovir combination therapy.
Park JG; Park SY
Clin Mol Hepatol; 2015 Sep; 21(3):242-8. PubMed ID: 26523269
[TBL] [Abstract][Full Text] [Related]
37. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
Chu M; Cho SM; Choe BH; Cho MH; Kwon S; Lee WK
J Pediatr Gastroenterol Nutr; 2012 Dec; 55(6):648-52. PubMed ID: 22688509
[TBL] [Abstract][Full Text] [Related]
38. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of switching to telbivudine plus adefovir in suboptimal responders to lamivudine plus adefovir.
Park H; Park JY; Kim SU; Kim DY; Han KH; Chon CY; Ahn SH
World J Gastroenterol; 2013; 19(43):7671-9. PubMed ID: 24431895
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of adefovir therapy for lamivudine-resistant hepatitis B virus infection in renal transplant recipients.
Lai HW; Chang CC; Chen TH; Tsai MC; Chen TY; Lin CC
J Formos Med Assoc; 2012 Aug; 111(8):439-44. PubMed ID: 22939662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]